Evidence map›Paper›PMID 30873046›Full record

ArticleFrontiers in physiology2019

Mechanism of Regulation of Big-Conductance Ca

Yinhang Wang, Jie Tao, Mengling Wang, Licai Yang, Fengling Ning, Hong Xin, Xudong Xu, Hui Cai, Weiguang Zhang, Ker Yu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  3. Article
  4. Immunity, Ion Channels and Epilepsy.International journal of molecular sciences · 2022
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Yinhang WangDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Jie TaoDepartment of Nephrology and Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Mengling WangDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Licai YangDepartment of Nephrology, Minhang Hospital, Fudan University, Shanghai, China.
Fengling NingDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Hong XinDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Xudong XuDepartment of Nephrology, Minhang Hospital, Fudan University, Shanghai, China.
Hui CaiRenal Division, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States.
Weiguang ZhangDepartment of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, Beijing, China.
Ker YuDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Xuemei ZhangDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Fudan University · CNMinhang District Central Hospital · CNAtlanta VA Medical Center · USShanghai University of Traditional Chinese Medicine · CNState Key Laboratory of Kidney Diseases

Funding

BLRD VA I01 BX000994
6 · The paper itself

Abstract

Podocytes, dynamic polarized cells wrapped around glomerular capillaries, are an essential component of the glomerular filtration barrier. BK channels consist of one of the slit diaphragm (SD) proteins in podocytes, interact with the actin cytoskeleton, and play vital roles in glomerular filtration. Mechanistic target of rapamycin (mTOR) complexes regulate expression of SD proteins, as well as cytoskeleton structure, in podocytes. However, whether mTOR complexes regulate podocyte BK channels is still unclear. Here, we investigated the mechanism of mTOR complex regulation of BK channels via real-time PCR, western blot, immunofluorescence, and patch clamping. Inhibiting mTORC1 with rapamycin or downregulating Raptor had no significant effect on BK channel mRNA and protein levels and bioactivity. However, the dual inhibitor of mTORC1 and mTORC2 AZD8055 and short hairpin RNA targeting Rictor downregulated BK channel mRNA and protein levels and bioactivity. In addition, MK2206, GF109203X, and GSK650394, which are inhibitors of Akt, PKCα, and SGK1, respectively, were employed to test the downstream signaling pathway of mTORC2. MK2206 and GF109203X had no effect on BK channel protein levels. MK2206 caused an obvious decrease in the current density of the BK channels. Moreover, GSK650394 downregulated the BK channel protein and mRNA levels. These results indicate mTORC2 not only regulates the distribution of BK channels through Akt, but also modulates BK channel protein expression via SGK1 in podocytes.

Indexed as

AktBK channelsmTORC2PKCαpodocyteSGK1

Identifiers

PMID30873046
PMCPMC6403181
OpenAlexW2920051472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.